Low-dose aspirin for the prevention of atherothrombosis.

This review considers the role of low-dose aspirin for the prevention of atherothrombosis, discussing the molecular mechanism of action of aspirin as well as clinical and epidemiologic studies of aspirin as an antiplatelet agent, with special emphasis on the benefits and risks in different patient populations.

[1]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[2]  G. Beck,et al.  A Randomized Trial of Aspirin to Prevent Colorectal Adenomas , 2003 .

[3]  R. Levin.  The puzzle of aspirin and sex. , 2005, The New England journal of medicine.

[4]  S. Corman,et al.  Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin , 2005, The Annals of pharmacotherapy.

[5]  Paul J. Harrison,et al.  Screening for Aspirin Responsiveness After Transient Ischemic Attack and Stroke: Comparison of 2 Point-of-Care Platelet Function Tests With Optical Aggregometry , 2005, Stroke.

[6]  G. FitzGerald,et al.  Estimated rate of thromboxane secretion into the circulation of normal humans. , 1986, The Journal of clinical investigation.

[7]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[8]  C. Patrono,et al.  Determinants of the interindividual variability in response to antiplatelet drugs , 2005, Journal of thrombosis and haemostasis : JTH.

[9]  G. Davı̀,et al.  Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.

[10]  A. Rebuzzi,et al.  Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. , 1997, Circulation.

[11]  C. Patrono,et al.  Improvement of renal function with selective thromboxane antagonism in lupus nephritis. , 1989, The New England journal of medicine.

[12]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[13]  M. Luca,et al.  Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein. , 2000, European journal of pharmacology.

[14]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[15]  C. Patrono,et al.  Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina , 2000, Circulation.

[16]  C. Patrono,et al.  Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. , 2001, The Journal of clinical investigation.

[17]  G. FitzGerald,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[18]  E. Ricciotti,et al.  Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.

[19]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[20]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[21]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[22]  A. Quick.  SALICYLATES AND BLEEDING: THE ASPIRIN TOLERANCE TEST , 1966, The American journal of the medical sciences.

[23]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[25]  G. FitzGerald,et al.  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.

[26]  D. Fitzgerald,et al.  Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. , 2000, Circulation.

[27]  D. Praticò,et al.  Superoxide Anion and Hydroxyl Radical Release by Collagen-induced Platelet Aggregation - Role of Arachidonic Acid Metabolism , 2000, Thrombosis and Haemostasis.

[28]  Catherine Kim,et al.  Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. , 2004, American journal of preventive medicine.

[29]  J. Eikelboom,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[30]  M. Cattaneo.  Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  V. Kalaria,et al.  Approach to “Aspirin Allergy” in Cardiovascular Patients , 2004, Circulation.

[32]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[33]  R Brian Haynes,et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.

[34]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[35]  W. Rogers,et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.

[36]  P. Koudstaal,et al.  Increased thromboxane biosynthesis is associated with poststroke dementia. , 1999, Stroke.

[37]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[38]  Timi Study,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .

[39]  Daniel Picot,et al.  The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.

[40]  G. FitzGerald,et al.  Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. , 2005, The Journal of clinical investigation.

[41]  M. Pfeffer,et al.  Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: A systematic review ☆ , 2003 .

[42]  C. Patrono,et al.  The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. , 1995, Seminars in nephrology.

[43]  R. Collins,et al.  Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collab , 2000, Journal of the American College of Cardiology.

[44]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.

[45]  M. Gimbrone,et al.  Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.

[47]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[48]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Á. Lanas,et al.  Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. , 2000, The New England journal of medicine.

[50]  R. de Caterina,et al.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.

[51]  R. Takolander,et al.  Does Low‐Dose Acetylsalicylic Acid Prevent Stroke After Carotid Surgery?: A Double‐blind, Placebo‐Controlled Randomized Trial , 1993, Stroke.

[52]  A. Zanchetti,et al.  Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. , 2002, Journal of hypertension.

[53]  Nzerue Cm.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001 .

[54]  G. FitzGerald,et al.  Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. , 1984, The New England journal of medicine.

[55]  J. McNeil,et al.  Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly , 2003, Drugs & aging.

[56]  Robert H Christenson,et al.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[57]  D. Fitzgerald,et al.  Selective cyclooxygenase-2 inhibition by nimesulide in man. , 1998, The Journal of pharmacology and experimental therapeutics.

[58]  G. FitzGerald,et al.  Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. , 1991, The New England journal of medicine.

[59]  S. Juul-Möller,et al.  Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. , 1992, Lancet.

[60]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[61]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[62]  C. Madden.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .

[63]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[64]  A. Maguire,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population , 2004, Circulation.

[65]  S. Narumiya,et al.  Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice , 2004 .

[66]  P. Majerus,et al.  Inhibition of platelet prostaglandin synthetase by oral aspirin. , 1978, The Journal of clinical investigation.

[67]  D. Dixon,et al.  Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis , 2001, The Journal of cell biology.

[68]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[69]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[70]  N. Gratsianskiĭ.  [Expert consensus document on the use of antiplatelet agents]. , 2004, Kardiologiia.

[71]  G. FitzGerald,et al.  Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.

[72]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[73]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[74]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[75]  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women , 2005 .

[76]  T. Barbui,et al.  Efficacy and safety of low-dose aspirin in polycythemia vera. , 2004, The New England journal of medicine.

[77]  C. Patrono,et al.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.

[78]  W. Rand,et al.  Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. , 1998, Journal of the American College of Cardiology.

[79]  M. Roncaglioni.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.

[80]  L. V. van Rossum,et al.  Proton‐pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo‐controlled trial , 2003, Alimentary pharmacology & therapeutics.

[81]  G. FitzGerald.  Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.

[82]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[83]  V. Fuster,et al.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[84]  A. Lowenthal.  The European Stroke Prevention Study , 1988, Acta neurologica Belgica.

[85]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[86]  S Moncada,et al.  Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. , 1979, The New England journal of medicine.

[87]  Á. Lanas,et al.  Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding , 2002, Expert opinion on drug safety.

[88]  G J Roth,et al.  Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[89]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[90]  L. G. García Rodríguez,et al.  Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. , 1998, Archives of internal medicine.

[91]  C. Patrono.  Aspirin resistance: definition, mechanisms and clinical read‐outs , 2003, Journal of thrombosis and haemostasis : JTH.

[92]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.